ATAI (atai Life Sciences NV) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Atai Life Sciences N.V. (ATAI) is recognized as a pioneer in psychedelic therapy, which provides the company with a high level of investor confidence. The annual volatility of net income per share TTM clearly demonstrates the business dynamics, where the value -171.80 describes the current level. Investments in unique molecules create a foundation for future revenues, while capital management efficiency is supported by a decentralized research model.
atai - פילוחים אנליטיים ומדדי מפתח (ATAI)

Year-over-year EPS (TTM) growth reflects the earnings per share dynamics over a rolling twelve-month period, allowing for an assessment of the business's actual capitalization efficiency. By analyzing the annual EPS TTM growth rate, an investor can see the impact of heavy R&D expenditures and FDA regulatory pressure on the net income of Atai Life Sciences N.V. (ATAI), where any fluctuations in this metric depend directly on the success of costly clinical trials.